About This Course
The Supreme Court’s decision not to review Purdue Pharma L.P. v. Accord Healthcare, Inc. (No. 24-1132) leaves the Federal Circuit’s opinion (No. 2023-1953, Dec. 30, 2024) as the leading authority on the nexus requirement for objective indicia of non-obviousness. This CLE program revisits Purdue’s approach at both the trial and appellate levels, offering a close examination of how arguments on obviousness and secondary considerations were developed and received.
Participants will explore how the Federal Circuit’s decision reshapes evidentiary expectations and strategic planning in patent cases. The session concludes with practical guidance for practitioners aiming to strengthen their advocacy in both prosecution and litigation contexts under this evolving body of law.
